Trials / Unknown
UnknownNCT03684863
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Randomised, Multicenter Phase II Study in Patients With HER-2 Positive Breast Cancer With Capecitabine Versus Observation With Pathologic Residual Tumors After Preoperative Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Shandong Cancer Hospital and Institute · Academic / Other
- Sex
- Female
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | observation |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2023-12-01
- Completion
- 2025-12-01
- First posted
- 2018-09-26
- Last updated
- 2018-09-26
Source: ClinicalTrials.gov record NCT03684863. Inclusion in this directory is not an endorsement.